Breast Cancer | Specialty

Dr. Baselga Compares mTOR Inhibitors in Breast Cancer

December 3rd 2012

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, compares results from two trials analyzing the mTOR inhibitors temsirolimus and everolimus in breast cancer.

Dr. Mayer on Tivozanib in Kidney and Breast Cancer

November 30th 2012

Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

Taking a Look at Four Noteworthy Studies

November 28th 2012

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

A Mainstay of Breast Cancer Treatment, Cytotoxics Class Must Grow

November 28th 2012

Despite the trend toward targeted therapies, cytotoxic drugs remain a mainstay of metastatic breast cancer treatment, and new therapies in that class are needed.

Dr. Weitzel on Combination Therapies in Breast Cancer

November 26th 2012

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

Patient and Physician Decision Practices Influence Chemotherapy Use in Older Patients With Breast Cancer

November 21st 2012

Older women with breast cancer who prefer less input from their physician when deciding on treatment are less likely to receive chemotherapy than women who prefer to rely on their physician to a greater degree, a recent study has found.

Dr. Baselga on pan-PI3K Inhibitors in Breast Cancer

November 20th 2012

José Baselga, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the investigation of pan-PI3K inhibitors for patients with metastatic breast cancer.

Treatment and Cost Implications of Pertuzumab

November 15th 2012

Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.

Molecular and Personalized Medicine in Breast Cancer

November 15th 2012

Managing Skeletal-Related Events in Breast Cancer, Part II

November 15th 2012

Managing Skeletal-Related Events in Breast Cancer, Part I

November 15th 2012

Emerging Therapies in Metastatic Breast Cancer

November 15th 2012

Chemotherapy in Advanced Breast Cancer

November 15th 2012

Management of Metastatic Breast Cancer, Part II

November 15th 2012

Improving the Management of Metastatic Breast Cancer, Part I

November 15th 2012

Dr. Debu Tripathy Previews the Phase II GRN1005 Study

November 14th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.

Dr. Hope Rugo Previews the 2012 SABCS Program

November 13th 2012

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

In Breast Cancer, Targeted Agents Boost Hormonal Therapies

November 12th 2012

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer

November 7th 2012

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.

Dr. Mamounas on Neoadjuvant Chemo for Breast Cancer

November 5th 2012

Terry P. Mamounas, MD, MPH, from Aultman Hospital Cancer Center, discusses the administration of neoadjuvant chemotherapy for patients with early-stage breast cancer.